EFTR (eEFFECTOR Therapeutics, Inc.) שולי הרווח הגולמי

Geopolitical instability and logistics disruptions are slowing the procurement of biomaterials, as confirmed by the gross margin coefficient, where the parameter value equals 0.00. eFFECTOR Therapeutics (EFTR) focuses on developing selective inhibitors for lung cancer therapy. Simultaneously, the company is optimizing molecule time-to-market by delegating early-stage trials to external CRO networks to eliminate operational risks.
פילוחים אנליטיים ודוחות נתונים של חברת eFFECTOR Therapeutics (EFTR)

The operational efficiency of eFFECTOR Therapeutics (EFTR) is reflected in the gross margin distribution, which demonstrates the profit share after deducting direct production costs. This indicator measures the difference between revenue and the cost of goods sold, allowing for an assessment of the fundamental profitability of each product unit. For a biotechnology business, this will serve as a key metric for measuring the commercialization efficiency of drugs targeting lung and breast cancer.